Publications by authors named "Manmath Patekar"

Claim this Profile
M
Model-Informed Drug Development for Ligelizumab in Patients With Chronic Spontaneous Urticaria.
Andrzej Bienczak, Aurelie Gautier, Eva Hua, Yan Ji, Emil Scosyrev, Manmath Patekar

CPT Pharmacometrics Syst Pharmacol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Efficacy and Safety of Ligelizumab as Re-Treatment in Patients With Chronic Spontaneous Urticaria.
Ana M Gimenez-Arnau, Marcus Maurer, Adam Reich, Chia-Yu Chu, Diana Deleanu, Manmath Patekar

Allergy· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Ligelizumab use for chronic spontaneous urticaria - Authors' reply.
Ana M Giménez-Arnau, Manmath Patekar, Vineeth Varanasi, Thomas Severin

Lancet· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.
Marcus Maurer, Luis Felipe Ensina, Ana Maria Gimenez-Arnau, Gordon Sussman, Michihiro Hide, Manmath Patekar

Lancet· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Secukinumab in Pediatric Patients with Plaque Psoriasis: Pooled Safety Analysis from Two Phase 3 Randomized Clinical Trials.
Michael Sticherling, Arjen F Nikkels, Ashraf M Hamza, Pearl Kwong, Jacek C Szepietowski, Manmath Patekar

Am J Clin Dermatol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comprehensive Assessment of Pharmacokinetics, Pharmacodynamics, and Tolerability of Ligelizumab in Healthy Volunteers and Patients with Chronic Spontaneous Urticaria to Optimize Its Subcutaneous Delivery System.
Yan Ji, Claudio Calonder, Tiina Kirsilä, Alis Burciu, Matjaz Tisu, Manmath Patekar

Pharmaceutics· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Secukinumab Across Subgroups and Overall Safety in Pediatric Patients with Moderate to Severe Plaque Psoriasis: Week 52 Results from a Phase III Randomized Study.
Nina Magnolo, Külli Kingo, Vivian Laquer, John Browning, Adam Reich, Manmath Patekar

Paediatr Drugs· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial.
Matthias Augustin, Kristian Reich, Paul Yamauchi, Andreas Pinter, Jerry Bagel, Manmath Patekar

Br J Dermatol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy, tolerability, patient usability, and satisfaction with a 2 mL pre-filled syringe containing secukinumab 300 mg in patients with moderate to severe plaque psoriasis: results from the phase 3 randomized, double-blind, placebo-controlled ALLURE study.
Bardur Sigurgeirsson, Knut Schäkel, Chih-Ho Hong, Isaak Effendy, Waldemar Placek, Manmath Patekar

J Dermatolog Treat· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Secukinumab demonstrates efficacy, safety, and tolerability upon administration by 2 ml autoinjector in adult patients with plaque psoriasis: 52-week results from MATURE, a randomized, placebo-controlled trial.
Bardur Sigurgeirsson, John Browning, Stephen Tyring, Jacek C Szepietowski, Raquel Rivera-Díaz, Manmath Patekar

Dermatol Ther· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 3 open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results.
Nina Magnolo, Külli Kingo, Vivian Laquer, John Browning, Adam Reich, Manmath Patekar

J Am Acad Dermatol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of secukinumab over 52 weeks in Chinese psoriasis patients with concomitant psoriatic arthritis.
Lin Cai, Jian-Zhong Zhang, Min Zheng, Shi-Fa Zhang, Manmath Patekar

Chin Med J (Engl)· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis.
Boni E Elewski, John W Baddley, Atul A Deodhar, Marina Magrey, Phoebe A Rich, Manmath Patekar

JAMA Dermatol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis.
Lin Cai, Jian-Zhong Zhang, Xu Yao, Jun Gu, Quan-Zhong Liu, Manmath Patekar

Chin Med J (Engl)· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of pharmacokinetics, safety and tolerability of secukinumab administered subcutaneously using different delivery systems in healthy volunteers and in psoriasis patients.
Gerard Bruin, Hans-Ulrich P Hockey, Phillip La Stella, Bárdur Sigurgeirsson, Rong Fu, Manmath Patekar

Br J Clin Pharmacol· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results).
Jerry Bagel, John Nia, Peter W Hashim, Manmath Patekar, Ana de Vera

Dermatol Ther (Heidelb)· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Iain B McInnes, Philip J Mease, Bruce Kirkham, Arthur Kavanaugh, Christopher T Ritchlin, Manmath Patekar

Lancet· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis